התחל במצב לא מקוון עם האפליקציה Player FM !
פודקאסטים ששווה להאזין
בחסות
![The Agile Brand with Greg Kihlström® podcast artwork](https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/32.jpg 32w, https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/64.jpg 64w, https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/128.jpg 128w, https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/256.jpg 256w, https://cdn.player.fm/images/25641206/series/oilf68jgHPTH2oAn/512.jpg 512w)
![The Agile Brand with Greg Kihlström® podcast artwork](/static/images/64pixel.png)
1 638: What's the ROI on those Big Game Ads? Featuring Nataly Kelly, CMO at Zappi 28:17
04_04 Castrate Resistant Metastatic Prostate Cancer
Manage episode 402595979 series 3335024
1. On continuation of ADT and ARAT switch
2. Systemic therapy options after progression
3. Improper mandated crossover
4. PARP inhibitors in prostate cancer
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Freedland SJ et al. NEJM. 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/
2. de Bono J et al. NEJM. 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/
3. Haslam A, Prasad V. Annals of Oncology. 2018;29(5):1079. doi:10.1093/ANNONC/MDY116
4. Parker C et al. NEJM. 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/
5. Khalaf DJ et al. Lancet Oncol. 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6
6. Saad F et al.. J Natl Cancer Inst. 2004;96(11):879-882. doi:10.1093/JNCI/DJH141
7. Sartor O et al. NEJM. 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/
8. de Wit R et al. NEJM. 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 פרקים
04_04 Castrate Resistant Metastatic Prostate Cancer
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 402595979 series 3335024
1. On continuation of ADT and ARAT switch
2. Systemic therapy options after progression
3. Improper mandated crossover
4. PARP inhibitors in prostate cancer
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Freedland SJ et al. NEJM. 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/
2. de Bono J et al. NEJM. 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/
3. Haslam A, Prasad V. Annals of Oncology. 2018;29(5):1079. doi:10.1093/ANNONC/MDY116
4. Parker C et al. NEJM. 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/
5. Khalaf DJ et al. Lancet Oncol. 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6
6. Saad F et al.. J Natl Cancer Inst. 2004;96(11):879-882. doi:10.1093/JNCI/DJH141
7. Sartor O et al. NEJM. 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/
8. de Wit R et al. NEJM. 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 פרקים
Alle episoder
×![Artwork](/static/images/128pixel.png)
1 04_08 Metastatic Renal Cell Carcinoma 24:16
![Artwork](/static/images/128pixel.png)
1 04_07 Localized Renal Cell Carcinoma 25:15
![Artwork](/static/images/128pixel.png)
1 04_06 Metastatic Urothelial Cancer 24:33
![Artwork](/static/images/128pixel.png)
1 04_05 Muscle Invasive Bladder Cancer 29:16
![Artwork](/static/images/128pixel.png)
1 01_14 Ampullary Carcinoma (Mini Discussion) 10:59
![Artwork](/static/images/128pixel.png)
1 04_04 Castrate Resistant Metastatic Prostate Cancer 24:50
![Artwork](/static/images/128pixel.png)
1 04_03 Metastatic Castrate Sensitive Prostate Cancer 29:02
![Artwork](/static/images/128pixel.png)
1 04_02 Adjuvant Options for Prostate Cancer 28:41
![Artwork](/static/images/128pixel.png)
1 04_01 Fundamentals of Localized Prostate Cancer 31:59
![Artwork](/static/images/128pixel.png)
1 03_13 Head and Neck Cancer – Locally advanced and metastatic 37:18
![Artwork](/static/images/128pixel.png)
1 03_12 Head and Neck Cancer – Background and adjuvant considerations 23:28
![Artwork](/static/images/128pixel.png)
1 03_11 Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma 29:40
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 03_09 Stage III NSCLC for the Medical Oncologist 27:46
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 03_06 Driver Mutations in Advanced NSCLC 34:06
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 03_05 NSCLC metastatic without driver mutations 31:52
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 03_01 The era of immune checkpoint inhibitors 22:59
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_10 BRCA Positive Breast Cancer in the Clinic 21:39
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_09 Triple Negative Breast Cancer 27:07
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_08 Early HER-2 positive breast cancer 25:27
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_07 HER-2 positive breast cancer: Considerations in advanced disease 25:12
![Talking About Tumors with Ryann and Ryan - A medical oncology podcast podcast artwork](/static/images/64pixel.png)
1 02_06 HER-2 Low Breast Cancer and Sacutuzumab Govetecan 22:30
ברוכים הבאים אל Player FM!
Player FM סורק את האינטרנט עבור פודקאסטים באיכות גבוהה בשבילכם כדי שתהנו מהם כרגע. זה יישום הפודקאסט הטוב ביותר והוא עובד על אנדרואיד, iPhone ואינטרנט. הירשמו לסנכרון מנויים במכשירים שונים.